Champix 1 mg (Varenicline Salicylate)

Adult dosage

Usual dose for adults Patients should set a quit date and start taking this medicine 1 week before that date. Alternatively, they may begin quitting between days 8 and 35 after starting this medicine. Take this medicine after meals with plenty of water. The recommended dose of this medicine is as follows: after dose titration over 1 week, administer 1 mg twice daily. Days 1–3 0.5 mg once daily Days 4–7 0.5 mg twice daily Day 8 until end of treatment 1 mg twice daily For patients who cannot tolerate the adverse reactions of this medicine, the dose may be reduced temporarily or permanently. The treatment period with this medicine is 12 weeks. For patients who successfully quit smoking with the first 12 weeks of treatment, it is recommended that this medicine be administered for an additional 12 weeks to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, consider gradually stopping smoking while taking this medicine. Reduce the amount smoked by 50% from the pretreatment level within the first 4 weeks after starting this medicine, and by a further 50% within the next 4 weeks. Continue to reduce smoking so that complete abstinence can be achieved by week 12. Administer this medicine for an additional 12 weeks for a total treatment period of 24 weeks. Encourage patients to stop smoking sooner if they feel ready. Patients who fail to quit smoking with the first 12 weeks of treatment or who resume smoking after treatment should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who failed to quit during the first 12 weeks of treatment or resumed smoking after treatment. No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 mL/min and ≤ 80 mL/min) to moderate (estimated creatinine clearance ≥ 30 mL/min and ≤ 50 mL/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 mL/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease undergoing hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. No dose adjustment is necessary in patients with hepatic impairment. Because renal function is more likely to be decreased in elderly patients, caution should be exercised when selecting the dose, and monitoring renal function may be useful.

Children's dosage

Use is not recommended in patients under 18 years of age because the safety and efficacy of this medicine have not been established in children.

This medicine is used to assist with smoking cessation. During administration, serious mental health issues such as suicidal thoughts, suicidal behavior, depression, anxiety, hallucinations, and aggression may occur, so caution is necessary. Patients with a history of psychiatric disorders should be monitored particularly closely, and any symptoms that appear should be discussed with a physician immediately. Patients with hypersensitivity or allergies to this medication should not take it. If you are pregnant or breastfeeding, consult your doctor about the potential effects of this medication on the fetus or infant. Nausea, headache, insomnia, unusual dreams, dyspepsia, and various other side effects may occur during use, with nausea being particularly common. If these symptoms are severe or persistent, inform your physician. Caution should be exercised when performing tasks that require concentration, such as driving or operating machinery, as this medication may cause drowsiness or dizziness. This medication is excreted through the kidneys, so patients with decreased renal function or the elderly may require dosage adjustment. There is no specific antidote for overdose, and appropriate treatment should be received based on symptoms. This medication does not significantly interact with other drugs; however, alcohol consumption may exacerbate side effects, so it is advisable to avoid alcohol while taking this medication. During treatment, changes in mental state, feelings of depression, and suicidal thoughts may occur, so if these symptoms arise, the medication should be stopped immediately, and medical advice sought. Children and adolescents under 18 years of age are not recommended to use this medication as its safety and efficacy have not been established.

• Suicidal thoughts
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medicine should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain the storage temperature between 1 degree to 30 degrees Celsius room temperature. Proper storage will help maintain the effectiveness of the medication over time.

Appearance

Light blue, double-convex, rectangular film-coated tablet

Package unit

28 tablets (14 tablets/PTPX2)